T. Rowe Price Investment Management Inc. Boosts Holdings in Avanos Medical, Inc. (NYSE:AVNS)

T. Rowe Price Investment Management Inc. increased its holdings in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 27.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,011,312 shares of the company's stock after buying an additional 644,267 shares during the quarter. T. Rowe Price Investment Management Inc. owned 6.55% of Avanos Medical worth $47,941,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Quantbot Technologies LP bought a new stake in Avanos Medical during the 4th quarter worth approximately $64,000. Tower Research Capital LLC TRC raised its stake in Avanos Medical by 493.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock worth $129,000 after acquiring an additional 6,714 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Avanos Medical during the 4th quarter worth approximately $162,000. Mariner LLC raised its stake in Avanos Medical by 18.0% during the 4th quarter. Mariner LLC now owns 10,655 shares of the company's stock worth $170,000 after acquiring an additional 1,625 shares during the period. Finally, US Bancorp DE raised its stake in Avanos Medical by 18.0% during the 4th quarter. US Bancorp DE now owns 14,093 shares of the company's stock worth $224,000 after acquiring an additional 2,147 shares during the period. Hedge funds and other institutional investors own 95.17% of the company's stock.

Avanos Medical Price Performance

Shares of Avanos Medical stock traded down $0.35 on Thursday, hitting $12.21. 145,846 shares of the company traded hands, compared to its average volume of 337,876. The stock has a market capitalization of $561.47 million, a P/E ratio of 35.86 and a beta of 1.15. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. Avanos Medical, Inc. has a 52 week low of $11.84 and a 52 week high of $25.36. The business has a 50-day simple moving average of $13.83 and a 200 day simple moving average of $16.58.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company had revenue of $179.60 million for the quarter, compared to analysts' expectations of $177.23 million. Research analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th.

Insider Buying and Selling

In related news, SVP Kerr Holbrook sold 7,000 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares in the company, valued at approximately $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.64% of the stock is currently owned by company insiders.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.